To evaluate the efficacy and safety of vamikibart in treatment-naïve patients with diabetic macular edema (DME) compared to anti-VEGF therapy.
Key Findings:
Vamikibart led to BCVA gains of approximately 6 letters from baseline across all doses.
15% to 23% of treatment-naïve patients gained 3 lines of vision (15 letters or more) with vamikibart.
CST improved by 50 µm to 70 µm from baseline across dosing arms.
30% to 40% of patients had CST less than 325 µm post-treatment.
Interpretation:
Vamikibart monotherapy demonstrated significant improvements in both visual and anatomical outcomes in DME patients, indicating its potential as an effective treatment option.
Limitations:
Higher incidence of ocular adverse events leading to treatment discontinuation in the vamikibart group.
Increased intraocular inflammation observed with the higher dose of vamikibart.
Conclusion:
Vamikibart shows promise as a distinct therapeutic approach targeting IL-6 in DME, warranting further exploration of combination therapies with anti-VEGF.
